2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1072

Fibrin-Triggered Chondrosynovial Adhesion As a Novel Mechanism of Cartilage Damage in Rheumatoid Arthritis
Abstract Number: 10

Fibroblast like Synoviocytes (FLS) Are Capable of Inducing Phenotypical Changes Including Class Switch Recombination (CSR) in Naive B Cells, but Additional Factors Are Required to Trigger Immunoglobulin Secretion
Abstract Number: 1029

Fibroblast-like Synoviocytes As Immune Effectors in the Pathogenesis of Synovial Lesion in Antibiotic-Refractory Lyme Arthritis
Abstract Number: 2025

Fibroblast-like Synoviocytes from Juvenile Idiopathic Arthritis and Controls Influence Expression of Bone Morphogenetic Protein Antagonists in Chondrocytes
Abstract Number: 932

Fibroblasts Senescence Is Observed in Rheumatoid and Osteoarthritic Synovial Tissues and Triggers a Pro-Inflammatory Program Ex Vivo
Abstract Number: 1836

Fibromyalgia Diagnosis and Biased Assessment: Sex, Prevalence, Biology and Bias
Abstract Number: 839

Fibromyalgia Is Identified in Routine Care on Indices Derived from an MDHAQ (MultiDimensional Health Assessment Questionnaire) with Robust Agreement with 2011 Revised Fibromyalgia Criteria Questionnaire
Abstract Number: 253

Fibromyalgia Patients Are Frequently Thought to be Challenging to Treat-Are They?
Abstract Number: 250

Fibromyalgia Patients Do Not Appear to Obsess about Their Symptoms Compared with Other Rheumatic Disease Patients
Abstract Number: 247

Fibromyalgia Patients Often Receive Several Rheumatic Disease Diagnoses
Abstract Number: 1838

Fibromyalgia, Beyond the 2016 Establishment. an Analysis of Novel Symptom Clusters for Differentiating Fibromyalgia from Other Chronic Pain Disorders
Abstract Number: 1821

Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study
Abstract Number: 1201

Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
Abstract Number: 854

First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 657

First Validation of Consensus Definitions for MRI Lesions in the Sacroiliac Joint By the Assessments in Spondyloarthritis International Society MRI Group

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].